| scholarly article | Q13442814 |
| P2093 | author name string | Nicholas S Heaton | |
| Alfred T Harding | |||
| P2860 | cites work | Seasonal inactivated influenza virus vaccines | Q24652665 |
| Advances and Challenges of Liposome Assisted Drug Delivery | Q26773160 | ||
| Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults | Q26781949 | ||
| Messenger RNA-based vaccines: progress, challenges, applications | Q27012738 | ||
| Cell culture-based influenza vaccines: A necessary and indispensable investment for the future | Q28084739 | ||
| Universal influenza virus vaccines and therapeutic antibodies | Q30151337 | ||
| Toward a universal influenza virus vaccine: prospects and challenges | Q30223478 | ||
| A fast track influenza virus vaccine produced in insect cells | Q30226454 | ||
| Influenza virus: a master of metamorphosis. | Q30327025 | ||
| Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. | Q30350403 | ||
| Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. | Q30360290 | ||
| Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process. | Q30365791 | ||
| DNA vaccines against influenza. | Q30366678 | ||
| Current and emerging cell culture manufacturing technologies for influenza vaccines. | Q30373128 | ||
| Development of high-yield influenza A virus vaccine viruses | Q30378710 | ||
| Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. | Q30385089 | ||
| Progress in developing virus-like particle influenza vaccines. | Q30386640 | ||
| The 2015 global production capacity of seasonal and pandemic influenza vaccine | Q30391889 | ||
| MF59 adjuvant: the best insurance against influenza strain diversity | Q30402018 | ||
| The influenza pandemic of 2009: lessons and implications | Q30403251 | ||
| Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model | Q30414135 | ||
| Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection | Q30423733 | ||
| Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies | Q30430925 | ||
| The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells. | Q33619857 | ||
| Advances in vaccine adjuvants | Q33764666 | ||
| Rapid evolution of RNA viruses | Q34174014 | ||
| Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans | Q34407701 | ||
| Current and next generation influenza vaccines: Formulation and production strategies | Q34479463 | ||
| Evolving complexities of influenza virus and its receptors | Q34765597 | ||
| Comparative glycomics analysis of influenza Hemagglutinin (H5N1) produced in vaccine relevant cell platforms. | Q34814833 | ||
| Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses | Q35130915 | ||
| Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine | Q35169258 | ||
| Nucleic acid vaccines. | Q35535126 | ||
| DNA vaccines in veterinary use. | Q35586830 | ||
| A potential peptide vaccine against two different strains of influenza virus isolated at intervals of about 10 years | Q35799165 | ||
| Development of high-yield influenza B virus vaccine viruses | Q36215805 | ||
| Vaccine adjuvants revisited | Q36750711 | ||
| An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge | Q37028384 | ||
| Traditional and new influenza vaccines | Q37035833 | ||
| Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability | Q37416925 | ||
| Cytoplasmic nucleic acid sensors in antiviral immunity | Q37576459 | ||
| The role of receptor binding specificity in interspecies transmission of influenza viruses | Q37996781 | ||
| The mechanism of action of MF59 - an innately attractive adjuvant formulation | Q38017390 | ||
| The history of MF59(®) adjuvant: a phoenix that arose from the ashes | Q38068952 | ||
| Influenza virosomes as vaccine adjuvant and carrier system | Q38124062 | ||
| Receptor-binding properties of modern human influenza viruses primarily isolated in Vero and MDCK cells and chicken embryonated eggs | Q38350824 | ||
| Committing the Oldest Sins in the Newest Kind of Ways-Antibodies Targeting the Influenza Virus Type A Hemagglutinin Globular Head | Q38535868 | ||
| Advances in the delivery of RNA therapeutics: from concept to clinical reality. | Q38706445 | ||
| Immune history and influenza virus susceptibility | Q39088963 | ||
| Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity. | Q39229311 | ||
| Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. | Q39741545 | ||
| A novel liposomal recombinant lipoimmunogen enhances anti-tumor immunity. | Q39778603 | ||
| Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes | Q40069102 | ||
| Rationally Designed Influenza Virus Vaccines That Are Antigenically Stable during Growth in Eggs | Q40170317 | ||
| DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial | Q40392276 | ||
| Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics | Q42755170 | ||
| Influenza virus surveillance, vaccine strain selection, and manufacture | Q45358113 | ||
| Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs | Q45418737 | ||
| Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice | Q45731471 | ||
| Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation | Q45867833 | ||
| Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. | Q47150783 | ||
| Chasing Seasonal Influenza — The Need for a Universal Influenza Vaccine | Q47162520 | ||
| Influenza Virus: Dealing with a Drifting and Shifting Pathogen | Q47548723 | ||
| Towards a universal influenza vaccine: different approaches for one goal | Q47548866 | ||
| Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018. | Q49981002 | ||
| MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico | Q50024815 | ||
| DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials | Q85047234 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | influenza vaccine | Q383260 |
| P304 | page(s) | 19 | |
| P577 | publication date | 2018-03-30 | |
| P1433 | published in | Vaccines | Q27725508 |
| P1476 | title | Efforts to Improve the Seasonal Influenza Vaccine | |
| P478 | volume | 6 |
| Q97652920 | A pooled genome-wide screening strategy to identify and rank influenza host restriction factors in cell-based vaccine production platforms |
| Q98186520 | A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season |
| Q92072257 | BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design |
| Q92360676 | Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): A Review in the Prevention of Influenza |
| Q92879909 | Current and novel approaches in influenza management |
| Q92853174 | Development of American-Lineage Influenza H5N2 Reassortant Vaccine Viruses for Pandemic Preparedness |
| Q91045420 | Establishment of an induced pluripotent cell line from Taiwan black silkie chick embryonic fibroblasts for replication-incompetent virus production |
| Q64079585 | Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine |
| Q64116962 | Novel Approaches for The Development of Live Attenuated Influenza Vaccines |
| Q92450354 | Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility |
| Q92152896 | Protein Vaccination Directs the CD4+ T Cell Response toward Shared Protective Epitopes That Can Be Recalled after Influenza Virus Infection |
| Q57166818 | The Future of Influenza Vaccines: A Historical and Clinical Perspective |
Search more.